vs

Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 27.7%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 31.3%).

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

HIVE vs PBYI — Head-to-Head

Bigger by revenue
HIVE
HIVE
1.2× larger
HIVE
$93.1M
$75.5M
PBYI
Growing faster (revenue YoY)
HIVE
HIVE
+190.8% gap
HIVE
218.6%
27.7%
PBYI
Faster 2-yr revenue CAGR
HIVE
HIVE
Annualised
HIVE
102.2%
31.3%
PBYI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
HIVE
HIVE
PBYI
PBYI
Revenue
$93.1M
$75.5M
Net Profit
$-91.3M
Gross Margin
-27.1%
69.3%
Operating Margin
22.7%
Net Margin
-98.1%
Revenue YoY
218.6%
27.7%
Net Profit YoY
-234.0%
EPS (diluted)
$-0.38
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIVE
HIVE
PBYI
PBYI
Q4 25
$93.1M
$75.5M
Q3 25
$87.3M
$54.5M
Q2 25
$45.6M
$52.4M
Q1 25
$46.0M
Q4 24
$29.2M
$59.1M
Q3 24
$22.6M
$80.5M
Q2 24
$32.2M
$47.1M
Q1 24
$43.8M
Net Profit
HIVE
HIVE
PBYI
PBYI
Q4 25
$-91.3M
Q3 25
$-15.8M
$8.8M
Q2 25
$35.0M
$5.9M
Q1 25
$3.0M
Q4 24
$68.2M
Q3 24
$80.0K
$20.3M
Q2 24
$-18.3M
$-4.5M
Q1 24
$-4.8M
Gross Margin
HIVE
HIVE
PBYI
PBYI
Q4 25
-27.1%
69.3%
Q3 25
4.7%
77.7%
Q2 25
-13.6%
76.5%
Q1 25
77.1%
Q4 24
-43.7%
76.4%
Q3 24
-66.1%
63.9%
Q2 24
-7.4%
77.4%
Q1 24
75.5%
Operating Margin
HIVE
HIVE
PBYI
PBYI
Q4 25
22.7%
Q3 25
17.6%
Q2 25
12.7%
Q1 25
8.7%
Q4 24
22.6%
Q3 24
27.4%
Q2 24
-4.6%
Q1 24
-5.3%
Net Margin
HIVE
HIVE
PBYI
PBYI
Q4 25
-98.1%
Q3 25
-18.1%
16.2%
Q2 25
76.8%
11.2%
Q1 25
6.5%
Q4 24
233.2%
Q3 24
0.4%
25.2%
Q2 24
-56.7%
-9.6%
Q1 24
-11.0%
EPS (diluted)
HIVE
HIVE
PBYI
PBYI
Q4 25
$-0.38
$0.26
Q3 25
$-0.07
$0.17
Q2 25
$0.18
$0.12
Q1 25
$0.06
Q4 24
$0.52
$0.40
Q3 24
$0.00
$0.41
Q2 24
$-0.17
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIVE
HIVE
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$559.3M
$130.3M
Total Assets
$624.0M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIVE
HIVE
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$40.5M
$101.0M
Q3 24
$31.7M
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
HIVE
HIVE
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
HIVE
HIVE
PBYI
PBYI
Q4 25
$559.3M
$130.3M
Q3 25
$624.6M
$115.3M
Q2 25
$560.5M
$104.7M
Q1 25
$97.1M
Q4 24
$430.9M
$92.1M
Q3 24
$275.5M
$71.1M
Q2 24
$268.6M
$48.5M
Q1 24
$51.0M
Total Assets
HIVE
HIVE
PBYI
PBYI
Q4 25
$624.0M
$216.3M
Q3 25
$693.0M
$202.9M
Q2 25
$628.7M
$194.9M
Q1 25
$196.2M
Q4 24
$478.6M
$213.3M
Q3 24
$334.7M
$220.7M
Q2 24
$205.0M
Q1 24
$214.1M
Debt / Equity
HIVE
HIVE
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIVE
HIVE
PBYI
PBYI
Operating Cash FlowLast quarter
$46.0M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIVE
HIVE
PBYI
PBYI
Q4 25
$46.0M
$14.4M
Q3 25
$-10.6M
$9.7M
Q2 25
$10.2M
$14.1M
Q1 25
$3.6M
Q4 24
$-28.5M
$15.6M
Q3 24
$-2.2M
$11.0M
Q2 24
$-4.4M
$1.0M
Q1 24
$11.2M
Free Cash Flow
HIVE
HIVE
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$-55.5M
$15.6M
Q3 24
$-34.7M
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
HIVE
HIVE
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
-189.9%
26.4%
Q3 24
-153.4%
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
HIVE
HIVE
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
92.5%
0.0%
Q3 24
143.9%
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
HIVE
HIVE
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
0.29×
2.41×
Q1 25
1.21×
Q4 24
-0.42×
Q3 24
-26.94×
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons